Kill, kill, kill! The worrying mortality of pharma pipelines
This article was originally published in Scrip
As reported yesterday in Scrip, pharma R&D activity is on the rise, with research by Citeline showing a 7.6% rise in the total number of drugs in the industry's pipeline (scripintelligence.com, 17 September 2012). But separate research by consultancy KMR Group, which collates data provided directly by responding companies (including this year 13 top US and European pharma firms with the notable exclusion of GlaxoSmithKline), highlights the possibility that increased R&D activity may be cause for concern rather than celebration. This is because it may be translating less rather than more frequently into marketable products.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.